Latest & greatest articles for fluticasone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluticasone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluticasone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluticasone

1. Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review. (Abstract)

Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review. Introduction: Recently, the generic formulation of FP/SAL FDC has been approved in COPD. Although FP/SAL FDC has been the first long-acting FDC approved in COPD, no systematic review assessed the effect of this combination for the treatment of COPD by considering specifically Phase IV studies. The aim of this review was to systematically assess the effect of FP/SAL FDC in COPD patients enrolled

2020 Expert review of respiratory medicine

2. Ocular symptoms improvement from intranasal triamcinolone compared with placebo and intranasal fluticasone propionate: A meta-analysis. (Full text)

Ocular symptoms improvement from intranasal triamcinolone compared with placebo and intranasal fluticasone propionate: A meta-analysis. Allergic rhinitis is a prevalent disease, which can be classed as seasonal (SAR) or perennial. In addition to nasal symptoms, up to 75% of sufferers experience itching, redness, and tearing of the eyes. Intranasal corticosteroids are effective in controlling the allergic nasal symptoms, and increasing evidence suggests that they also can relieve some (...) of the allergic ocular symptoms.To evaluate the magnitude of efficacy of triamcinolone acetonide (TAA) compared with placebo or fluticasone propionate (FP) on ocular symptom improvement in patients with SAR.A meta-analysis of summary data from 8 randomized, double- or single-blind trials, assessing mean change in total or individual (tearing, redness, and itching) eye symptoms was conducted. Trials that administered a daily dose of 220 μg TAA vs placebo or 200 μg FP over at least 2 weeks' duration

2020 Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology PubMed abstract

3. Intranasal Azelastine and Fluticasone as Combination Therapy for Allergic Rhinitis: Systematic Review and Meta-analysis. (Abstract)

Intranasal Azelastine and Fluticasone as Combination Therapy for Allergic Rhinitis: Systematic Review and Meta-analysis. Combination therapy with intranasal azelastine and fluticasone propionate is an option for treatment of allergic rhinitis. This systematic review and meta-analysis examines existing literature to determine efficacy in treating allergic rhinitis compared to monotherapy.The PubMed, EMBASE, Cochrane, and MEDLINE databases were systematically searched for randomized controlled (...) therapy compared to monotherapy or placebo. Meta-analysis revealed superiority of combination therapy in reducing Total Nasal Symptom Score compared to placebo (mean change from baseline: -2.41; 95% confidence interval [CI], -2.82 to -1.99; P < .001; I2 = 60%), azelastine (mean change from baseline: -1.40; 95% CI, -1.82 to -0.98; P < .001; I2 = 0%), and fluticasone (mean change from baseline: -0.74; 95% CI, -1.17 to -0.31; P < .001; I2 = 12%).Current evidence supports both efficacy and superiority

2020 Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery

4. The efficacy and safety of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol in treating pediatric asthma: a systematic review and meta-analysis. (Full text)

The efficacy and safety of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol in treating pediatric asthma: a systematic review and meta-analysis. 31852314 2019 12 19 1473-2300 2019 Dec 18 The Journal of international medical research J. Int. Med. Res. The efficacy and safety of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol in treating pediatric asthma: a systematic review and meta-analysis. 300060519889442 10.1177 (...) University, Qingdao, China. Xu Tao T Department of Respiratory Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China. Hu Haiyan H Center of Diagnosis and Treatment of Breast Disease, The Affiliated Hospital of Qingdao University, Qingdao, China. eng Journal Article 2019 12 18 England J Int Med Res 0346411 0300-0605 IM Pediatric asthma fluticasone formoterol meta-analysis randomized controlled trial salmeterol 2019 12 20 6 0 2019 12 20 6 0 2019 12 20 6 0 aheadofprint 31852314 10.1177

2019 The Journal of international medical research PubMed abstract

5. Fluticasone furoate/umeclidinium/vilanterol (COPD) – Addendum to Commission A18-15

Fluticasone furoate/umeclidinium/vilanterol (COPD) – Addendum to Commission A18-15 1 Translation of addendum A18-46 Fluticasone furoate/umeclidinium/vilanterol (COPD) – Addendum to Commission A18-15 (Version 1.0; Status: 26 July 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 26 July 2018 1.0 Commission: A18-46 Version: Status: IQWiG Reports (...) – Commission No. A18-46 Fluticasone furoate/ umeclidinium/vilanterol (COPD) – Addendum to Commission A18-15 1 Addendum A18-46 Version 1.0 FF/UMEC/VI – Addendum to Commission A18-15 26 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Fluticasone furoate/umeclidinium/vilanterol (COPD) – Addendum to Commission A18-15 Commissioning agency: Federal Joint Committee Commission awarded on: 09 July

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

6. Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial (Full text)

Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial Topical steroid treatments for eosinophilic esophagitis (EoE) include swallowed fluticasone from a multi-dose inhaler (MDI) or oral viscous budesonide (OVB) slurry, but the 2 have never been compared. We assessed whether OVB was more effective than MDI for initial treatment of patients with EoE.In a double-blind, double-dummy trial, patients with a new diagnosis of EoE were (...) randomly assigned to groups given 8 weeks of either OVB (1 mg/4 mL) twice daily plus a placebo inhaler (n = 56) or fluticasone MDI (880 μg) twice daily plus a placebo slurry (n = 55). Primary outcomes were post-treatment maximum eosinophil counts per high-power field (eos/hpf) and a validated dysphagia score (dysphagia symptom questionnaire [DSQ]) at week 8. Secondary outcomes included endoscopic severity (validated EoE endoscopic reference score), histologic response (<15 eos/hpf), and safety.In

2019 EvidenceUpdates PubMed abstract

7. Fluticasone/formoterol (Flutiform) - the regular treatment of asthma in children aged 5 to 12 years

Fluticasone/formoterol (Flutiform) - the regular treatment of asthma in children aged 5 to 12 years 1 Published 10 June 2019 1 Product update SMC2178 fluticasone propionate/formoterol fumarate metered dose inhaler 50 microgram/5 microgram (flutiform®) Napp Pharmaceuticals Ltd 10 May 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice (...) is summarised as follows: ADVICE: following an abbreviated submission fluticasone propionate/formoterol fumarate (flutiform®) is accepted for use within NHSScotland. Indication under review: the regular treatment of asthma in children aged 5 to 12 years where the use of a combination product (an inhaled corticosteroid and a long-acting ß 2 agonist) is appropriate: • For patients not adequately controlled with inhaled corticosteroids and 'as required' inhaled short-acting ß 2 agonist. Or • For patients

2019 Scottish Medicines Consortium

8. Fluticasone furoate/umeclidinium/vilanterol (COPD) - Benefit assessment according to §35a Social Code Book V

Fluticasone furoate/umeclidinium/vilanterol (COPD) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Fluticasonfuroat/Umeclidinium/Vilanterol (mit LABA + LAMA vorbehandelte COPD) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 February 2019). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German (...) original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A18-79 Fluticasone furoate/ umeclidinium/vilanterol (COPD pretreated with LABA + LAMA) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-79 Version 1.0 Fluticasone furoate/umeclidinium/vilanterol (COPD pretreated with LABA + LAMA) 13 February 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

9. NAVIGATE II: randomized, double-blind trial of the exhalation delivery system with fluticasone (EDS-FLU) for nasal polyposis (Full text)

NAVIGATE II: randomized, double-blind trial of the exhalation delivery system with fluticasone (EDS-FLU) for nasal polyposis Chronic rhinosinusitis is common and sometimes complicated by nasal polyps (NPs). Corticosteroid nasal sprays are often unsatisfactory because they are ineffective at delivering medication to high/deep sites of inflammation.We sought to assess whether an exhalation delivery system with fluticasone (EDS-FLU) capable of high/deep drug deposition improves outcomes.Patients

2018 EvidenceUpdates PubMed abstract

10. Fluticasone

Fluticasone Top results for fluticasone - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for fluticasone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

11. Fluticasone/formoterol (flutiform k-haler) - for the regular treatment of asthma

Fluticasone/formoterol (flutiform k-haler) - for the regular treatment of asthma Abbreviated Submission fluticasone propionate/ formoterol fumarate 50microgram/5microgram, 125microgram/5microgram pressurised inhalation, suspension (Flutiform k-haler ® ) SMC2016 Napp Pharmaceuticals Ltd 4 May 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice (...) is summarised as follows: ADVICE: following an abbreviated submission fluticasone propionate/ formoterol fumarate (Flutiform k-haler ® ) is accepted for use within NHS Scotland. Indication under review: for the regular treatment of asthma where the use of a combination product [an inhaled corticosteroid (ICS) and a long-acting ß 2-agonist (LABA)] is appropriate: • For patients not adequately controlled with ICS as ‘as required’ inhaled short-acting ß2- agonist or • For patients already adequately controlled

2018 Scottish Medicines Consortium

12. Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy)

Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) Chronic obstructiv Chronic obstructive pulmonary disease: e pulmonary disease: fluticasone furoate, umeclidinium and vilanterol fluticasone furoate, umeclidinium and vilanterol (T (T relegy) relegy) Evidence summary Published: 14 June 2018 nice.org.uk/guidance/es18 pathways K Ke ey points y points The content of this evidence summary was up-to-date in June 2018. See summaries of product (...) characteristics (SPC), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Regulatory status: Regulatory status: Fluticasone furoate/umeclidinium/vilanterol (Trelegy, GlaxoSmithKline UK) received a European marketing authorisation in November 2017. This triple-therapy inhaler contains an inhaled corticosteroid (ICS), long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA). It is licensed for maintenance treatment of adults with moderate- to-severe

2018 National Institute for Health and Clinical Excellence - Advice

13. Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk (Full text)

Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk Many patients with chronic obstructive pulmonary disease (COPD) have an accelerated loss of lung function. It is unclear whether drug treatment can modify this in patients with moderately severe disease.In a prespecified analysis of the key secondary outcome in SUMMIT (Study to Understand Mortality and Morbidity), we investigated whether (...) the inhaled corticosteroid fluticasone furoate (FF; 100 μg), the long-acting β-agonist vilanterol (VI; 25 μg), or their combination (FF/VI) modified the rate of decline in FEV1 compared with placebo. We also investigated how baseline covariates affected this decline.Spirometry was measured every 12 weeks in this event-driven, randomized, placebo-controlled trial of 16,485 patients with moderate COPD and heightened cardiovascular risk. An average of seven spirometric assessments per subject among

2018 EvidenceUpdates PubMed abstract

14. Fluticasone furoate / umeclidinium / vilanterol (Trelegy Ellipta) - maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD)

Fluticasone furoate / umeclidinium / vilanterol (Trelegy Ellipta) - maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) Published 12 February 2018 Product Update fluticasone furoate, umeclidinium, vilanterol (as trifenatate) 92 micrograms / 55 micrograms / 22 micrograms inhalation powder (Trelegy ® Ellipta ® ) SMC No 1303/18 GlaxoSmithKline UK 12 January 2018 The Scottish Medicines Consortium (SMC) has completed its assessment (...) of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission fluticasone furoate / umeclidinium / vilanterol (as trifenatate) (Trelegy ® Ellipta ® ) is accepted for restricted use within NHS Scotland. Indication under review: maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated

2018 Scottish Medicines Consortium

15. Trelegy Ellipta - fluticasone furoate umeclidinium vilanterol - Chronic obstructive pulmonary disease (COPD)

Trelegy Ellipta - fluticasone furoate umeclidinium vilanterol - Chronic obstructive pulmonary disease (COPD) fluticasone furoate/umeclidinium/vilanterol | CADTH.ca Find the information you need fluticasone furoate/umeclidinium/vilanterol fluticasone furoate/umeclidinium/vilanterol Last Updated: September 19, 2018 Result type: Reports Project Number: SR0562-000 Product Line: Generic Name: fluticasone furoate umeclidinium vilanterol Brand Name: Trelegy Ellipta Manufacturer: GlaxoSmithKline Inc

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

16. Arbesda RespiClick - fluticasone propionate / salmeterol xinafoate - Asthma

Arbesda RespiClick - fluticasone propionate / salmeterol xinafoate - Asthma fluticasone propionate / salmeterol xinafoate | CADTH.ca Find the information you need fluticasone propionate / salmeterol xinafoate fluticasone propionate / salmeterol xinafoate Last Updated: March 22, 2019 Result type: Reports Project Number: SR0540-000 Product Line: Generic Name: fluticasone propionate / salmeterol xinafoate Brand Name: Arbesda RespiClick Manufacturer: TEVA Canada Innovation Indications: Asthma (...) request granted - Reconsideration requested Applicant's request for reconsideration placed on CDEC agenda December 12, 2018 CDEC Final Recommendation issued to applicant and drug plans December 19, 2018 CDEC Final Recommendation posted December 21, 2018 Final CADTH review report(s) and patient input posted January 17, 2019 Tags asthma, dry powder inhalers, respiratory, respiclick; arbesda; fluticasone propionate; salmeterol; dry powder inhaler; asthmatic; asthmatics Files Follow us: © 2019 Canadian

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

17. Aermony RespiClick - fluticasone propionate - Asthma

Aermony RespiClick - fluticasone propionate - Asthma fluticasone propionate | CADTH.ca Find the information you need fluticasone propionate fluticasone propionate Last Updated: December 21, 2018 Result type: Reports Project Number: SR0539-000 Product Line: Generic Name: fluticasone propionate Brand Name: Aermony RespiClick Manufacturer: TEVA Canada Innovation Indications: Asthma Submission Type: New Project Status: Complete Biosimilar: No Date Recommendation Issued: December 19, 2018 (...) , 2018 CDEC Final Recommendation posted December 21, 2018 Final CDR review report(s) and patient input posted January 21, 2019 Tags asthma, dry powder inhalers, respiratory, aermony; fluticasone propionate; dry powder inhaler; asthmatic; asthmatics; respiclick Files Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

18. fluticasone furoate/vilanterol (Breo Ellipta )

fluticasone furoate/vilanterol (Breo Ellipta ) fluticasone furoate/vilanterol | CADTH.ca Find the information you need fluticasone furoate/vilanterol fluticasone furoate/vilanterol Last Updated: December 14, 2017 Result type: Reports Project Number: SR0524-000 Product Line: Generic Name: fluticasone furoate/vilanterol Brand Name: Breo Ellipta Manufacturer: GlaxoSmithKline Inc. Indications: COPD Submission Type: Resubmission Project Status: Withdrawn Biosimilar: No Key Milestones 2 Call

2017 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

19. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. (Full text)

Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Evidence for management of asthma comes from closely monitored efficacy trials done in highly selected patient groups. There is a need for randomised trials that are closer to usual clinical practice.We did an open-label, randomised, controlled, two-arm effectiveness trial at 74 general practice clinics in Salford and South Manchester, UK (...) . Patients aged 18 years or older with a general practitioner's diagnosis of symptomatic asthma and on maintenance inhaler therapy were randomly assigned to initiate treatment with a once-daily inhaled combination of either 100 μg or 200 μg fluticasone furoate with 25 μg vilanterol or optimised usual care and followed up for 12 months. The primary endpoint was the percentage of patients who achieved an asthma control test (ACT) score of 20 or greater or an increase in ACT score from baseline of 3

2017 Lancet Controlled trial quality: predicted high PubMed abstract

20. Comparative Meta-Analysis of the Efficacy of Once-Daily Fluticasone Furoate 100 µG Versus Twice-Daily Fluticasone Propionate 250 µG in Adolescents and Adults with Persistent Asthma. (Full text)

Comparative Meta-Analysis of the Efficacy of Once-Daily Fluticasone Furoate 100 µG Versus Twice-Daily Fluticasone Propionate 250 µG in Adolescents and Adults with Persistent Asthma. Fluticasone furoate and fluticasone propionate are recommended options for prophylactic maintenance treatment of persistent asthma. Using data from two previous clinical studies (GSK studies: FFA109685/NCT00603278, FFA112059/NCT01159912), this meta-analysis compared change from baseline in clinic visit mean (...) trough forced expiratory volume in 1 s (FEV1) with fluticasone furoate 100 µg once-daily (FF100) versus fluticasone propionate 250 µg twice-daily (FP250) in adolescents and adults with persistent asthma. Using a DerSimonian-Laird random-effects model (primary meta-analysis), there was no statistically significant difference between FF100 and FP250 in change from baseline in trough FEV1 (-1.7 mL [95% CI -80.4, +77.0], p = 0.9664) and FF100 was non-inferior to FP250. Supporting analyses using least

2017 Lung PubMed abstract